This live web event has ended. Thank you for attending.
It is critical to prioritize safety in drug development studies. The
bioanalysis data plays a vital role in the decisions taken during the
development process and it is crucial to ensure that the results obtained are
reliable. Therefore, prioritizing risk mitigation in bioanalysis is essential
to maintain the integrity of drug development studies.
Ligand binding assays (LBA) are widely used to quantify biopharmaceuticals and biomarkers, as well as to evaluate immunogenicity in preclinical and clinical studies. In this presentation, we will highlight key factors to keep in mind when developing a ligand binding assay. The focus will be on creating a robust assay with high specificity and selectivity. We will show real-life common challenges through case studies and suggest solutions based on our extensive experience in developing ligand binding assays.